Renal amyloidosis overview

Revision as of 18:32, 8 August 2018 by Aditya Ganti (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Renal amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography or Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:Renal amyloidosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal amyloidosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal amyloidosis overview

CDC on Renal amyloidosis overview

Renal amyloidosis overview in the news

Blogs on Renal amyloidosis overview

Directions to Hospitals Treating Cystic fibrosis

Risk calculators and risk factors for Renal amyloidosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Omer Kamal, M.D. [2]

Overview

Nicolaus Fontanus was the first to describe amyloidosis based on the result of an autopsy while Rudolph Virchow was the first to introduce the term amyloidosis. Renal amyloidosis can be classified according to the site of amyloid deposition into glomerular, vascular, and tubular amyloidosis. Suggested mechanisms of renal involvement include abnormal protein production or hereditary mutation. If left untreated, renal amyloidosis may progress into end stage renal disease. Common complications include chronic renal failure and nephrotic syndrome. After a few years, renal amyloidosis eventually leads to end stage renal disease and it may be progressed in presence of certain factors such as steroid administration, renal vein thrombosis, infections and surgery. There is insufficient evidence to recommend routine screening for renal amyloidosis. Renal biopsy is the gold standard test for the diagnosis of renal diagnosis. The mainstay of treatment for renal amyloidosis is to decrease the production or increase clearing of amyloid. Pharmacologic medical therapies for renal amyloidosis include colchicine, azathioprine, dimethylsulfoxide, chlorambucil, methotrexate, cyclophosphamide and TNF-alpha antagonists (ie, etanercept, infliximab, and adalimumab).

Historical Perspective

Nicolaus Fontanus was the first to describe amyloidosis based on the result of an autopsy while Rudolph Virchow was the first to introduce the term amyloidosis.

Classification

Renal amyloidosis can be classified according to the site of amyloid deposition into glomerular, vascular, and tubular amyloidosis.

Pathophysiology

Suggested mechanisms of renal involvement include abnormal protein production or hereditary mutation.

Causes

Most common causes of renal amyloidosis include primary and secondary amyloidosis. Other causes include transthyretin and fibrinogen amyloid deposition.

Differentiating Renal amyloidosis from Other Diseases

Epidemiology and Demographics

The incidence is 97 to 140 cases per 100,000 individuals. The incidence of renal amyloidosis increases with age; the median age at diagnosis is 65 years.

Risk Factors

Common risk factors in the development of renal amyloidosis may be environmental and genetic such as heterozygous mutations in the genes for lysozyme, apolipoprotein AI, apolipoprotein AII, or fibrinogen A alpha-chain.

Screening

There is insufficient evidence to recommend routine screening for renal amyloidosis.

Natural History, Complications, and Prognosis

If left untreated, renal amyloidosis may progress into end stage renal disease. Common complications include chronic renal failure and nephrotic syndrome. After a few years, renal amyloidosis eventually leads to end stage renal disease and it may be accelerated by some factors such as steroid administration, renal vein thrombosis, infections and surgery.

Diagnosis

Diagnostic Study of Choice

Renal biopsy is the gold standard test for the diagnosis of renal diagnosis

History and Symptoms

The majority of patients with renal amyloidosis have proteinuria. Swelling is very common in lower limbs. Numbness or tingling in hands or feet (carpal tunnel syndrome) is a less common finding.

Physical Examination

Physical examination of patients with renal amyloidosis is usually remarkable for swelling, hepatosplenomegaly, facial or neck purpura and macroglossia. Fatigue and unintentional weight loss, are common in patients with AL amyloidosis. Tachycardia/bradycardia depends on the accompanying complication. Pulmonary fine crackles, faint pulmonary auscultation, suggestive of pleural effusion, decreased tactile fremitus and dull percussion.

Laboratory Findings

In patients with secondary amyloidosis, urinalysis should be routinely examined. Laboratory findings consistent with the diagnosis of renal amyloidosis include proteinuria and increased serum creatinine

Electrocardiogram

There are no ECG findings associated with renal amyloidosis.

X-ray

There are no definitive findings on x-ray associated with renal amyloidosis.

Echocardiography and Ultrasound

There are no echocardiography/ultrasound findings associated with renal amyloidosis

CT scan

There are no CT scan findings associated with renal amyloidosis

MRI

There are no MRI findings associated with renal amyloidosis.

Other Imaging Findings

There are no other imaging findings associated with renal amyloidosis

Other Diagnostic Studies

Kidney biopsy can represent amyloid deposition as vascular, tubulo-interstitial and/or glomerular deposits. All types of amyloidogenic proteins show affinity for Congo red dye.

Treatment

Medical Therapy

The mainstay of treatment for renal amyloidosis is to decrease the production or increase clearing of amyloid. Pharmacologic medical therapies for renal amyloidosis include colchicine, azathioprine, dimethylsulfoxide, chlorambucil, methotrexate, cyclophosphamide and TNF-alpha antagonists (ie, etanercept, infliximab, and adalimumab).

Surgery

In renal amyloidosis, surgery is usually reserved for patients developed with end stage renal disease. The patients with renal amyloidosis are good candidates for transplantation. In primary amyloidosis, renal transplantation is considered and it will improve long-term survival and quality of life.

Primary Prevention

There are no established measures for the primary prevention of renal amyloidosis.

Secondary Prevention

Treatment of the primary disease and underlying cause will provide favorable renal outcome. Template:WikiDoc Sources